Mirikizumab is a recombinant humanized monoclonal antibody that selectively targets interleukin-23 (IL-23) by binding to the p19 subunit of IL-23. It is a biologic therapeutic used in the treatment of inflammatory diseases, particularly moderate-to-severe ulcerative colitis. Mirikizumab is marketed under the brand name Omvoh.
As a biologic active pharmaceutical ingredient, Mirikizumab is produced using recombinant biotechnology and requires specialized manufacturing, purification and analytical characterization. The molecule is an IgG4 monoclonal antibody designed to selectively inhibit IL-23-mediated inflammatory signaling.
Mirikizumab API is relevant to pharmaceutical biotechnology, biologics development, analytical research, formulation development and manufacturing of finished pharmaceutical products.
Mirikizumab is a humanized monoclonal antibody directed against the p19 subunit of IL-23. IL-23 is a cytokine involved in the regulation of inflammatory immune responses.
By selectively binding to IL-23 and preventing its interaction with the IL-23 receptor, Mirikizumab inhibits IL-23-mediated signaling. This mechanism helps reduce inflammatory activity associated with certain immune-mediated diseases.
Mirikizumab is an important biologic molecule for research and pharmaceutical development involving IL-23 pathway inhibition, inflammatory bowel disease and targeted immunomodulatory therapies.
| Parameter | Specification |
|---|---|
| Appearance | White crystalline powder or crystals |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 1.0% |
| Water Content | NMT 1.0% |